ATOS Atossa Genetics Inc.

-0.08  -3%
Previous Close 2.62
Open 2.62
Price To Book 2.62
Market Cap 23176095
Shares 9,124,447
Volume 176,160
Short Ratio
Av. Daily Volume 3,621,310

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2018
Breast cancer - patients who are not responding to Tamoxifen
Phase 2 data due 2Q 2019.
Mammographic breast density (MBD)
Phase 2 trial ongoing - noted December 28, 2017.
Cuctal carcinoma in situ(DCIS) - invasive breast cancer
Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives. Final data January 9, 2019 confirmed objectives met.
Male breast cancer and Gynecomastia
Phase 2 commencement of enrollment announced July 13, 2018.
Breast cancer - window of opportunity setting

Latest News

  1. Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
  2. "Bull Market Hopping?"
  3. Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
  4. Atossa Genetics Announces Receipt of $10 Million
  5. What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?
  6. Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
  7. Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
  8. "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter
  9. Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
  10. Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force
  11. Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter
  12. Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019
  13. Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics
  14. 4 Healthcare Stocks Looking To Set January Highs
  15. Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen
  16. Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape
  17. "The Roller Coaster Ride Continues"
  18. Edison issues outlook on Atossa Genetics (ATOS)
  19. Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
  20. ''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter